The Baker Heart and Diabetes Institute has sold clinical research subsidiary Nucleus Network to Crescent Capital Partners. The institute holds an option on 20 per cent of the business but it will, “invest a large percentage of the sale proceeds to underpin the long-term financial stability of the Institute.” Good-o but how much that might be is not known. The Baker declines to disclose the sale price.
Campus Morning Mail is an independent newsletter written and published by Stephen Matchett, formerly a long-serving journalist at The Australian newspaper. The daily e-news column receives no undisclosed funding or other assistance from any organisation or individual.
Subscribe